Metrion Biosciences strengthens team with three key appointments

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research organisation (CRO) and drug discovery company, has promoted Clare Rutty to CFO and welcomes two new hires in Sue Peffer as Head of Marketing and Leanne Clarke as HR Officer. Following the recent announcement of new equity financing, these appointments strengthen the leadership team, ensuring a strong foundation as the Company sets its sights on continued growth.

Already an established colleague, Clare Rutty has been promoted to Chief Financial Officer (CFO). Since joining Metrion, Clare has been instrumental in progressing the reporting and financial controls as the business has grown from reported turnover of £1.5m in the financial year to 31st December 2018 to £5.3m in the year to 31st December 2022, with further growth in 2023.

Since 2022 the Metrion team has grown by 55% to 42 employees, and the business has established new services and revenue lines. Clare was closely involved in the £2.7m new equity funding round in 2021 led by Gresham House Ventures and more recently in the £3.7m of new equity financing led by Maven Capital Partners, which closed in December 2023.

In the new role of Head of Marketing, Sue Peffer will manage all marketing activities. Sue has a background in marketing in the life sciences sector, including at Cresset, a computational chemistry software and services company, Capsugel (now Lonza), and The Automation Partnership (now Sartorius Stedim Biotech). Sue’s appointment also boosts female representation on the Metrion Leadership Team.

As a services company, Metrion’s staff are its most valuable asset. In the new role of Human Resources Officer, Leanne Clarke will ensure Metrion attracts top talent and maintains a workplace where everyone can reach their full potential.

“Ensuring Metrion appoints staff of the highest calibre is paramount to our success. We are also proud that women currently make up 42% of Metrion employees – well over the 39% average for women working in UK drug discovery R&D1. These new appointments and Clare’s promotion are reflective of the growth and increasing maturity of our business, and in line with our goal of equal representation within our workforce.”

Dr Andrew Southan, Chief Executive, Metrion Biosciences

“I’m pleased to join the Board at the time of closing the 2023 funding round and look forward to working with the directors and the wider Metrion team as the business continues to develop.”

Clare Rutty, CFO, Metrion Biosciences

“I’m delighted to join Metrion at this exciting time for the business. To do so at the point when other female colleagues are promoted and welcomed makes me proud to be part of an organisation that recognises female talent.”

Sue Peffer, Head of Marketing, Metrion Biosciences

“I am thrilled to join Metrion and am eager to contribute to its continued growth and success in a highly challenging market. I am excited to collaborate with the talented team and foster a supportive environment in which employees can thrive and contribute to advancements in the biosciences field.”

Leanne Clarke, HR Officer, Metrion Biosciences

For more information:


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Metrion Biosciences Limited. (2024, March 11). Metrion Biosciences strengthens team with three key appointments. News-Medical. Retrieved on May 18, 2024 from

  • MLA

    Metrion Biosciences Limited. "Metrion Biosciences strengthens team with three key appointments". News-Medical. 18 May 2024. <>.

  • Chicago

    Metrion Biosciences Limited. "Metrion Biosciences strengthens team with three key appointments". News-Medical. (accessed May 18, 2024).

  • Harvard

    Metrion Biosciences Limited. 2024. Metrion Biosciences strengthens team with three key appointments. News-Medical, viewed 18 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metrion Biosciences appoints Dr Benedetta Montagnini as Head of European Business Development